The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the United States and Mexico.
Additional analyses of the trial are ongoing, according to the company, and will be submitted to peer-reviewed journals for publication. Novavax to seek US authorization of its Covid-19 vaccine in third quarter, CEO saysThe trial results appear consistent with the efficacy and safety profile the vaccine previously showed in a Phase 3 trial conducted in the United Kingdom, Dr. Gregory Glenn, president of research and development for Novavax, told CNN.
Novavax's coronavirus vaccine, called NVX-CoV2373, differs from the three vaccines already in use in the United States. The vaccine relies on what is called recombinant nanoparticle technology and Novavax's adjuvant, called Matrix-M, to stimulate an immune response.The two mRNA vaccines that were authorized last year in the United States -- from Pfizer/BioNTech and Moderna -- both use genetic material to stimulate an immune response.
I invested $100 in bitcoin online trade with help from blincredits and made $1000 within a few hours duration trading from home. so excited and think it's nice sharing the news.
Please help me! My name is Lin donglong, an employee of China telecom fuzhou branch. Company manager huang fei (communist party of China) organized the leadership of the gang of evil forces brutal persecution: surveillance location, insult,abuse, framed to take nude photos of me
Happy birthday Mr. President realDonaldTrump POTUS45 Best President ever! 2024 The real GOAT!!
❤️
Novavax researchers also took a close look at sequencing data for 54 of the 77 Covid - 19 cases in the study .
There were 77 Covid -19 cases that emerged among participants during the study , according to Novavax .Sixty three cases were in the people in the placebo group and 14 in the vaccine group .
Good. Another vaccine to help get the world back to normal sooner
The company said the vaccine was ' generally well- tolerated ' and common side effects included pain at the injection site , lasting less than three days , and fatigue ,, headache and muscle pain , lasting less than two days .
good
Some of the participants were given a placebo and some were administered two doses of the Novavax vaccine 21 days apart .
The study launched in December and enrolled 29,960 adults across 113 sites in the United States and six sites in Mexico .
I’ll wait for the peer review.
Phase 3 phase 2 is still experimental,only this time we de people are the gunie pigs lab rats...yep!they invent the bio germ in a lab&tested it full scale on us unsuspecting ones,their objective cripple 🌎's economic system=CCP's XPING EMPOROR OF 🌎 China's way or de highway...
Great news
Additional analysis of the trial are ongoing ,, according to the company ,and will be submitted to peer reviewed journals for publication.
Generally well tolerated... Well that could have been worded better
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Reuters - 🏆 2. / 97 Read more »
Source: ABC - 🏆 471. / 51 Read more »
Source: AP - 🏆 728. / 51 Read more »
Source: THR - 🏆 411. / 53 Read more »
Source: DEADLINE - 🏆 109. / 63 Read more »
Source: Reuters - 🏆 2. / 97 Read more »